Origin invests in early-stage unquoted businesses and smaller quoted companies. Most of Origin's portfolio companies have a technology focus, for example high-value manufacturing, life sciences, software and IT infrastructure with nvestment transactions typically of £50k – £2m.
Sanofi leverages new biotechnologies to more effectively target disease pathways and bring breakthrough medicines to patients faster. Part of our innovation effort relies on a variety of different partnering models with external specialists to access early stage and cutting-edge technologies and new innovation. BioSeed offers an opportunity to meet innovative companies in our areas of interest that we have not met before.
Sygnature Discovery is a private equity-backed drug discovery company. We work with our partners via flexible deal structures from company formation, through seed funding to Series A. Recent investments include Peak Proteins, a protein crystallography company, and Step Pharma, an auto-immune diseases-focused biotechnology company. As well as investing itself, Sygnature works with universities and biotech start-ups to raise funds from non-dilutive sources and venture capital companies.
Tim is an angel investor and a highly experienced and extremely well-connected pharmaceutical industry executive with a wide range of skills and expertise in commercial strategy, marketing and medical affairs.
Waimangu is building a venture capital fund to invest in early stage healthcare and technology companies focussed on London and the South East of the UK